MATCHPOINT - Medulloblastoma Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade
This study is testing a new way to treat children and young adults with recurrent medulloblastoma, a type of brain tumor. Researchers are combining personalized immune cell therapies and vaccines with a drug that helps the body's immune system fight cancer cells more effectively.
This trial is for patients aged 4 to 30 who have specific types of medulloblastoma that have returned after treatment. Candidates need to be healthy enough for daily activities and must be able to provide tumor tissue for the study.
Participants will receive a combination of personalized vaccines made from their own cells and immune-boosting medicines. This process involves careful monitoring of how the immune system responds to these therapies to ensure safety and effectiveness.
The study is currently recruiting patients and is taking place at medical centers in Washington, D.C. and Gainesville, Florida.
- 1This is a Phase 1 study focusing on the safety of a new multi-therapy approach.
- 2The treatment uses personalized vaccines made from your own cells to help your immune system fight cancer.
- 3Participation requires being able to undergo surgery or biopsy to provide tumor tissue for analysis.
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.